Fig 2: Phosphorylation of (A) JNK at Thr183/Tyr185, (B) SMAD2 at Ser245/250/255, (C) p38 at Thr180/Tyr182, (D) YAP at Ser127 and (E) TAZ at Ser89 at baseline (Pre), immediately after exercise (post) and following 90 or 180 minutes of recovery. Data presented in the bars are the mean ± SEM (n = 8). White bars represent the normoxia trial and blue bars represent the hypoxia trial. *P < .05 vs Pre, # P < .05 vs normoxia

Fig 3: PLA2G16 promotes the malignant progression of CRC through the Hippo signaling pathway. (A) Differentially expressed gene in PLA2G16-siRNA-1 and PLA2G16-siRNA-2 compared to Ctrl-siRNA. (B) The same differentially expressed gene in PLA2G16-siRNA-01 and PLA2G16-siRNA-02. (C) RT-qPCR to validate the results of same genes in PLA2G16- siRNA-01 and PLA2G16-siRNA-02 by RNA-seq. (D) KEGG pathway enrichment analysis of PLA2G16-regulated pathway. (E) The mRNA levels of YAP, TAZ, LATS1, and MST1 were measured by RT-qPCR after HT29 and SW480 were transfected with PLA2G16-siRNA. (F) The protein levels of LATS1, p-LATS1, YAP, p-YAP, TAZ, and p-TAZ upon PLA2G16 knockdown in HT29 and SW480 cells. (G) The protein expression of YAP, p-YAP, TAZ, and p-TAZ after PLA2G16-overexpression. (H) Immunofluorescence assay to detect the protein expression of YAP and TAZ in HT29 and SW480 cells, the magnification was 600 ×. (I) The expressions of YAP and TAZ in the cytoplasmic and nucleus. (J-K) RT-qPCR analysis of the mRNA expression of the downstream genes of the Hippo signaling pathway after PLA2G16 knockdown or PLA2G16-overexpression. (L) Co-IP was to study how PLA2G16 regulated the Hippo signaling pathways.